In RA, upadacitinib has been evaluated in two phase II dose ranging studies: BALANCE I (in TNF inadequate responders) and BALANCE II (in methotrexate inadequate responders), in which a significant and rapid dose-response were seen for ACR20, 50 and 70 responses [49,53]. This evidence concerns the gene TNF and rheumatoid arthritis.